Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-02-13 7:02 pm Sale | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 570,976 2.600% | -868,403![]() (-60.33%) | Filing History |
2023-01-27 6:01 pm Purchase | 2022-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.900% | 1,439,379![]() (New Position) | Filing History |
2022-02-11 4:19 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Ally Bridge MedAlpha Master Fund L.P. | 604,774 2.800% | 604,774![]() (New Position) | Filing History |
2022-02-11 4:17 pm Sale | 2021-12-31 | 13G | Cogent Biosciences, Inc. COGT | Ally Bridge MedAlpha Master Fund L.P. | 1,501,591 3.800% | -121,000![]() (-7.46%) | Filing History |
2022-02-11 4:17 pm Purchase | 2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 393,052 6.300% | 89,740![]() (+29.59%) | Filing History |
2021-02-12 4:15 pm Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | Ally Bridge MedAlpha Master Fund L.P. | 1,622,591 5.100% | 1,622,591![]() (New Position) | Filing History |
2021-01-07 07:36 am Purchase | 2020-12-31 | 13G | MIRAGEN THERAPEUTICS INC MGEN | Ally Bridge MedAlpha Master Fund L.P. | 929,979 9.990% | 929,979![]() (New Position) | Filing History |
2020-12-18 4:20 pm Purchase | 2020-12-08 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 303,313 5.400% | 303,313![]() (New Position) | Filing History |